MedPath

Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

Not Applicable
Recruiting
Conditions
Septic Shock
Interventions
Device: Low Level Transcutaneous Vagus Nerve Stimulation
Registration Number
NCT03992378
Lead Sponsor
University of Oklahoma
Brief Summary

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. It is the most expensive healthcare condition to treat in United States and has a mortality rate of nearly 30%. It is widely known that exaggerated inflammation and imbalance between sympathetic and parasympathetic arms of the autonomic nervous system (ANS) contribute to progression and adverse outcomes in sepsis. The role of unchecked inflammation and unregulated ANS as a potential treatment target is an important gap in our knowledge that should be explored.

Cholinergic anti-inflammatory pathway (CAP) is an intricate network where the ANS senses inflammation by vagus nerve afferents and tries to regulate it by vagus nerve efferents to the reticuloendothelial system. The central hypothesis of this pilot clinical trial is that transcutaneous vagus nerve stimulation (TVNS) at tragus of the external ear can activate the CAP to suppress inflammation and improve autonomic imbalance as measured by inflammatory cytokine levels and heart rate variability (HRV) analysis. The investigators plan to randomize patients with septic shock into active and sham stimulation groups and study the effects of vagal stimulation on inflammatory cytokines, HRV and a clinical severity score of sepsis. Both groups will continue to receive the standard of care treatment for sepsis irrespective of group assignments. The investigators hypothesize that 4 hours of TVNS will suppress inflammatory markers and improve the balance between sympathetic and parasympathetic arms of ANS as measured by HRV, resulting in improved Sequential Organ Failure Assessment Score (SOFA). The preliminary data generated from this pilot study will lay the foundation for a larger clinical trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
34
Inclusion Criteria

Septic shock (meeting severe sepsis and having persistent systolic blood pressure <90mmHg despite adequate fluid resuscitation).

Exclusion Criteria
  • Unilateral or bilateral vagotomy
  • History of myocardial infarction or stroke in the last 1 year
  • Recurrent vasovagal syncope
  • Sick sinus syndrome without pacemaker
  • Bifascicular heart block
  • 2nd or 3rd-degree heart block
  • Hypotension due to autonomic dysfunction
  • Pregnant women
  • Prisoners and patients with suicidal ideation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham ControlLow Level Transcutaneous Vagus Nerve StimulationPatients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
Active TreatmentLow Level Transcutaneous Vagus Nerve StimulationPatients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
Primary Outcome Measures
NameTimeMethod
Change in Inflammatory Cytokine Tumor Necrosis Factor AlphaBaseline to 4 hours and baseline to 24 hours post stimulation

Serum inflammatory cytokine

Secondary Outcome Measures
NameTimeMethod
Change in Heart Rate VariabilityBaseline to 4 hours post stimulation

Time domain and frequency domain measures of heart rate variability

Change in Sequential Organ Failure Assessment ScoreBaseline to 24 hours post stimulation

Sequential Organ Failure Assessment Score calculation

Trial Locations

Locations (1)

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath